---
created: 2025-04-13
updated: 2025-04-13T10:52
id: e8<.SH7ZN#
specialty: immuno
specialty_id: 121
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::denosumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::11-musculoskeletal-skin-connective-tissue::04-pharm::07-denosumab
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::05-gi-&-endocrine::03-thyroid,-parathyroid-&-adrenal::02-bisphosphonates,-raloxifene,-denosumab,-calcitonin
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::cancer-immunotherapy
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
Because RANKL is also expressed on **T Helper** cells, a side effect of Denosumab treatment is **immunosuppression**

---

# Answer
T Helper cells use RANKL to stimulate Dendritic Cell Maturation  Immunosuppression is manifested as increased risk of infections, cellulitis